Cormorant Asset Management, LP

Cormorant Asset Management, LP has filed trades across 31 companies (mainly through SEC (Form 4)), most often in Corbus Pharmaceuticals Holdings, Inc., EyePoint, Inc. and Immuneering Corp. The record holds 145 filings, for trades running from 29 May 2018 to 28 April 2026.

Market trades split into 100 purchases (€376.1M) and 19 sales (€16.1M). The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 option exercise. 2026 to date brings no purchases and 1 sale.

Half of the purchases are above €1.7M and half below. 19 out of 79 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Looking at 10 purchases old enough to measure, the stock rose over the following 90 days in 20% of cases; the median change was -13.5%. This is a record of the past, not a forecast.

The latest filing, published on 30 April 2026, reports an open-market sale of €8.4M in Bright Minds Biosciences Inc. The most recent open-market purchase was published on 19 February 2025, 612 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.